IMMUNIC, INC. current report, 23 May 2017

Business Context and Reporting Period

This Form 8-K is a current report filed by Vital Therapies, Inc. (noted as Immunics, Inc. in request metadata) on May 23, 2017. The filing documents the results of the company's 2017 Annual Meeting of Stockholders held on the same date. The registrant is an emerging growth company incorporated in Delaware.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results rather than financial performance.

Material Changes and Voting Results

The primary material event reported is the outcome of the Annual Meeting. Of the 40,894,876 shares outstanding, 33,963,019 shares (approximately 83.05%) were represented at the meeting.

1. Election of Class III Directors

Four nominees were elected to serve until the 2020 annual meeting. The voting results were as follows:

Nominee Votes For Votes Withheld Broker Non-Votes
Cheryl L. Cohen 20,294,286 2,308,875 11,359,858
Errol R. Halperin 19,980,860 2,622,301 11,359,858
J. Michael Millis, M.D. 18,701,157 3,902,004 11,359,858
Lowell E. Sears 20,295,029 2,308,132 11,359,858

2. Ratification of Independent Auditor

Stockholders ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2017.

For Against Abstain Broker Non-Votes
33,858,775 99,039 5,205 0

Guidance, Outlook, and Risks

The filing text does not provide guidance, outlook, management commentary on operations, risks, contingencies, or unusual items.

Key Facts for Investor Verification

  • Company Name Discrepancy: Verify the current legal name of the registrant, as the request metadata lists "IMMUNIC, INC." while the filing header explicitly states "VITAL THERAPIES, INC."
  • Board Composition: Confirm the tenure of the newly elected Class III directors (Cheryl L. Cohen, Errol R. Halperin, J. Michael Millis, M.D., and Lowell E. Sears) through the 2020 annual meeting.
  • Auditor Status: Note that PricewaterhouseCoopers LLP has been ratified as the auditor for the fiscal year ending December 31, 2017.
  • Shareholder Participation: Approximately 83% of outstanding shares were represented at the meeting, indicating high engagement.